Media

Bourne Partners Represents Concordia Healthcare Corp. in Its Sale of Three Injectable Products to IGI Laboratories

BOURNE PARTNERS REPRESENTS CONCORDIA HEALTHCARE CORP. IN ITS SALE OF THREE INJECTABLE PRODUCTS TO IGI LABORATORIES

Bourne Partners Acts as Exclusive Financial Advisor to Concordia on the Acquisition


CHARLOTTE, N.C., October 6, 2015—
Concordia Pharmaceuticals, Inc., S.A.R.L. has sold three currently marketed injectable products to New Jersey-based specialty generic company IGI Laboratories (NYSE MKT: IG). Bourne Partners, a leading healthcare and consumer healthcare investment banking, merchant banking, and investment firm, acted as the exclusive financial advisor to Concordia on the transaction.

The products included in the package are: Zantac (ranitidine) injection indicated in some hospitalized patients with pathological hypersecretory conditions or intractable duodenal ulcers; Fortaz (ceftazidime) indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms; and Zinacef (cefuroxime sodium) indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms.

According to IMS Health data quoted by IGI, the current addressable market in the USA for these products is estimated at $26 million as of August 2015.

Jason Grenfell-Gardner, president and chief executive of IGI, commented:

This transaction delivers contribution to our fourth quarter of 2015 financial results. It is consistent with our TICO strategy, and accelerates our commercial entry into the sterile injectable market. These products, while branded, compete in genericized markets for these product forms, and thus should allow us to leverage our existing value chain for sales, marketing, and distribution of these products.  In addition, Zinacef and Fortaz complement IGI's pipeline of hospital-administered anti-infective injectables, which is a market segment we believe is best served by a portfolio approach.  Our business development team will continue to focus on acquiring currently marketed assets that are aligned with our TICO strategy. 

About Bourne Partners (BP)
Headquartered in Charlotte, N.C., Bourne Partners is a financial advisory, investment and consulting firm founded in 2001 that focuses solely on fulfilling the unique needs of established healthcare and pharmaceutical companies across the globe. Originally founded as a pharmaceutical investment firm, BP has evolved its service offerings in an effort to form enduring relationships with the healthcare and consumer companies it chooses to serve. For additional information, visit bourne-partners.com.

 

 

Receive Your Report By Email